Sedia Biosciences Corporation of Portland, Oregon announced today that
it has received a Notice of Award granting Phase II funding of its
previous Small Business Innovation Research (SBIR) grant from the
National Institute of Allergy and Infectious Diseases (NIAID) of the
National Institutes of Health. The Phase II funding is to continue
development and commercialization for diagnostic use of Sedia's HIV-1
Limiting Antigen ("LAg")-Avidity EIA, a novel single well enzyme assay
based on U.S. Centers for Disease Control and Prevention ("CDC")
licensed technology. The assay measures HIV-1 antibody avidity or
"binding ability," a measure of antibody maturation and indirectly
disease progression. Sedia is already selling the HIV-1 LAg-Avidity EIA
for use in surveillance and population studies as a Research Use Only
product as a tool to measure HIV incidence, monitor the spread of the
HIV epidemic and identify hot spots of new infections. Current users are
primarily the CDC, Ministries of Public Health, and other public health
groups around the world. The Phase II funding will enable Sedia to
develop an FDA-regulated version of the assay for diagnostic use to
determine how recently the individual was infected.

It has been estimated that as many as 40-50% of all new HIV infections
are the result of transmission from infected individuals who themselves
were recently infected. Recently infected individuals also tend to have
significantly higher viral loads than individuals with longer term
infections, presenting a potentially higher risk of transmission to
uninfected sexual partners or others that may be exposed to their blood,
such as drug users who share needles with them. HIV scientists and
epidemiologists have advocated earlier identification of recently
infected individuals to "triage" them for more aggressive treatment,
follow-up and contact tracing, to reduce these risks of transmssion.
Having a tool to enable identification of recently infected individuals
can also provide an additional means to develop treatments tailored to
the individual.

"Sedia has been very pleased with the reception that the Sedia™ HIV-1
LAg-Avidity EIA has received in the public health community and we are
excited about the possibility of providing this as an aid to
characterizing individual infections to better combat the HIV epidemic,"
stated Dr. Ronald Mink, Sedia's President and Chief Science Officer.
"The ongoing support for this assay from CDC, NIH and a broad range of
public health groups around the world, we believe, demonstrates the
value of making this assay available to clinicians treating infected
individuals enabling them to better understand the disease state in such
individuals."

Research reported in this press release was supported by the National
Institute of Allergy and Infectious Diseases of the National Institutes
of Health under award number R44AI097001. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health. Additional
information about the Sedia™ HIV-1 LAg-Avidity EIA is also available at www.hivincidence.com.

About Sedia Biosciences Corporation:

Sedia Biosciences Corporation (www.sediabio.com)
is a U.S.-based healthcare company focused on the development and
commercialization of novel in vitro diagnostic and epidemiological
tests. The company is dedicated to advancing access to medical care by
developing innovative diagnostic and monitoring products that enable
more cost effective and expanded testing for infectious diseases and
other conditions. Based in Portland, Oregon, Sedia develops,
manufactures, licenses and sells in vitro diagnostic and epidemiological
tests as well as specimen collection devices.

Statements in this press release that are not historical facts are
forward-looking statements within the meaning of the Securities Act of
1933, as amended.Those statements include statements regarding
the intent, belief or current expectations of the Company and its
management.Such statements reflect management's current views,
are based on certain assumptions and involve risks and uncertainties.Actual results, events, or performance may differ materially from the
above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not
limited to, the Company's ability to obtain additional financing, if and
as needed, and access funds from its existing financing arrangements
that will allow it to continue its current and future operations and
whether demand for its test products in domestic and international
markets will generate sufficient revenues to achieve positive cash flow
and profitability.The Company undertakes no obligation to
publicly update these forward-looking statements to reflect events or
circumstances that occur after the date hereof or to reflect any change
in the Company's expectations with regard to these forward-looking
statements or the occurrence of unanticipated events.